BidaskClub upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a hold rating to a buy rating in a report published on Tuesday morning.
Several other research firms have also recently commented on SCMP. Maxim Group reaffirmed a buy rating and issued a $23.00 price target on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. Leerink Swann initiated coverage on Sucampo Pharmaceuticals in a report on Monday, August 21st. They issued an outperform rating and a $15.00 price target for the company. Zacks Investment Research raised Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price target for the company in a report on Tuesday, October 17th. initiated coverage on Sucampo Pharmaceuticals in a report on Wednesday, November 15th. They issued a buy rating and a $14.00 price target for the company. Finally, ValuEngine raised Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, December 1st. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $16.40.
Sucampo Pharmaceuticals (SCMP) opened at $14.20 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market capitalization of $627.25, a P/E ratio of 9.21, a price-to-earnings-growth ratio of 4.00 and a beta of 1.47. Sucampo Pharmaceuticals has a twelve month low of $9.30 and a twelve month high of $17.24.
In other news, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.13% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. HPM Partners LLC acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter worth approximately $1,307,000. Louisiana State Employees Retirement System grew its position in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 100 shares during the last quarter. Trexquant Investment LP bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $122,000. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $127,000. Finally, JPMorgan Chase & Co. bought a new stake in Sucampo Pharmaceuticals during the 2nd quarter worth approximately $117,000. 65.31% of the stock is owned by institutional investors and hedge funds.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.